Reported Earnings • Jun 01
Full year 2026 earnings released: EPS: ₹0.54 (vs ₹2.44 in FY 2025) Full year 2026 results: EPS: ₹0.54 (down from ₹2.44 in FY 2025). Revenue: ₹1.20b (down 1.8% from FY 2025). Net income: ₹7.05m (down 72% from FY 2025). Profit margin: 0.6% (down from 2.1% in FY 2025). Over the last 3 years on average, earnings per share has increased by 1% per year but the company’s share price has fallen by 11% per year, which means it is significantly lagging earnings. Tillkännagivande • May 22
Trident Texofab Limited to Report Q4, 2026 Results on May 28, 2026 Trident Texofab Limited announced that they will report Q4, 2026 results on May 28, 2026 Valuation Update With 7 Day Price Move • May 06
Investor sentiment deteriorates as stock falls 16% After last week's 16% share price decline to ₹44.87, the stock trades at a trailing P/E ratio of 20.9x. Average trailing P/E is 24x in the Retail Distributors industry in India. Total loss to shareholders of 30% over the past three years. Valuation Update With 7 Day Price Move • Apr 09
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to ₹55.17, the stock trades at a trailing P/E ratio of 25.7x. Average trailing P/E is 22x in the Retail Distributors industry in India. Total loss to shareholders of 20% over the past three years. Valuation Update With 7 Day Price Move • Mar 16
Investor sentiment deteriorates as stock falls 23% After last week's 23% share price decline to ₹44.97, the stock trades at a trailing P/E ratio of 20.9x. Average trailing P/E is 21x in the Retail Distributors industry in India. Total loss to shareholders of 27% over the past three years. New Risk • Mar 08
New major risk - Market cap size The company's market capitalization is less than US$10m. Market cap: ₹917.0m (US$9.98m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (1.9x net interest cover). Shareholders have been substantially diluted in the past year (46% increase in shares outstanding). Market cap is less than US$10m (₹917.0m market cap, or US$9.98m). Minor Risks Share price has been volatile over the past 3 months (7.6% average weekly change). Large one-off items impacting financial results. Reported Earnings • Feb 16
Third quarter 2026 earnings released: EPS: ₹0.39 (vs ₹0.30 in 3Q 2025) Third quarter 2026 results: EPS: ₹0.39 (up from ₹0.30 in 3Q 2025). Revenue: ₹262.2m (down 17% from 3Q 2025). Net income: ₹5.70m (up 90% from 3Q 2025). Profit margin: 2.2% (up from 0.9% in 3Q 2025). Over the last 3 years on average, earnings per share has increased by 5% per year but the company’s share price has increased by 20% per year, which means it is tracking significantly ahead of earnings growth. New Risk • Feb 13
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 7.4% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (1.9x net interest cover). High level of non-cash earnings (24% accrual ratio). Shareholders have been substantially diluted in the past year (46% increase in shares outstanding). Minor Risks Share price has been volatile over the past 3 months (7.4% average weekly change). Market cap is less than US$100m (₹1.97b market cap, or US$21.7m). Valuation Update With 7 Day Price Move • Feb 09
Investor sentiment deteriorates as stock falls 23% After last week's 23% share price decline to ₹153, the stock trades at a trailing P/E ratio of 77.9x. Average trailing P/E is 25x in the Retail Distributors industry in India. Total returns to shareholders of 79% over the past three years. Tillkännagivande • Feb 06
Trident Texofab Limited to Report Q3, 2026 Results on Feb 12, 2026 Trident Texofab Limited announced that they will report Q3, 2026 results at 3:30 PM, Indian Standard Time on Feb 12, 2026 Tillkännagivande • Nov 05
Trident Texofab Limited to Report Q2, 2026 Results on Nov 13, 2025 Trident Texofab Limited announced that they will report Q2, 2026 results on Nov 13, 2025 Tillkännagivande • Aug 28
Trident Texofab Limited, Annual General Meeting, Sep 25, 2025 Trident Texofab Limited, Annual General Meeting, Sep 25, 2025, at 16:00 Indian Standard Time. Reported Earnings • Aug 15
First quarter 2026 earnings released: EPS: ₹0.72 (vs ₹0.69 in 1Q 2025) First quarter 2026 results: EPS: ₹0.72 (up from ₹0.69 in 1Q 2025). Revenue: ₹285.2m (up 11% from 1Q 2025). Net income: ₹10.2m (up 46% from 1Q 2025). Profit margin: 3.6% (up from 2.7% in 1Q 2025). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 8% per year but the company’s share price has increased by 23% per year, which means it is tracking significantly ahead of earnings growth. Tillkännagivande • Aug 07
Trident Texofab Limited to Report Q1, 2026 Results on Aug 12, 2025 Trident Texofab Limited announced that they will report Q1, 2026 results on Aug 12, 2025 Reported Earnings • May 30
Full year 2025 earnings released: EPS: ₹2.38 (vs ₹1.07 in FY 2024) Full year 2025 results: EPS: ₹2.38 (up from ₹1.07 in FY 2024). Revenue: ₹1.25b (up 26% from FY 2024). Net income: ₹25.1m (up 132% from FY 2024). Profit margin: 2.0% (up from 1.1% in FY 2024). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 10% per year but the company’s share price has increased by 23% per year, which means it is tracking significantly ahead of earnings growth. Tillkännagivande • May 21
Trident Texofab Limited to Report Q4, 2025 Results on May 29, 2025 Trident Texofab Limited announced that they will report Q4, 2025 results on May 29, 2025 New Risk • Apr 21
New major risk - Shareholder dilution The company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 35% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (0.8x net interest cover). Shareholders have been substantially diluted in the past year (35% increase in shares outstanding). Minor Risks Large one-off items impacting financial results. Market cap is less than US$100m (₹2.34b market cap, or US$27.3m). Reported Earnings • Feb 04
Third quarter 2025 earnings released: EPS: ₹0.30 (vs ₹0.55 in 3Q 2024) Third quarter 2025 results: EPS: ₹0.30 (down from ₹0.55 in 3Q 2024). Revenue: ₹314.3m (up 37% from 3Q 2024). Net income: ₹3.00m (down 46% from 3Q 2024). Profit margin: 1.0% (down from 2.4% in 3Q 2024). Over the last 3 years on average, earnings per share has increased by 12% per year but the company’s share price has increased by 30% per year, which means it is tracking significantly ahead of earnings growth. Valuation Update With 7 Day Price Move • Jan 31
Investor sentiment deteriorates as stock falls 15% After last week's 15% share price decline to ₹157, the stock trades at a trailing P/E ratio of 73.2x. Average trailing P/E is 32x in the Retail Distributors industry in India. Total returns to shareholders of 196% over the past three years. Tillkännagivande • Jan 29
Trident Texofab Limited to Report Q3, 2025 Results on Feb 03, 2025 Trident Texofab Limited announced that they will report Q3, 2025 results on Feb 03, 2025 Valuation Update With 7 Day Price Move • Oct 24
Investor sentiment improves as stock rises 40% After last week's 40% share price gain to ₹105, the stock trades at a trailing P/E ratio of 49x. Average trailing P/E is 47x in the Retail Distributors industry in India. Total returns to shareholders of 141% over the past three years. Recent Insider Transactions • Oct 18
MD & Executive Chairman recently sold ₹54m worth of stock On the 16th of October, Hardik Desai sold around 1m shares on-market at roughly ₹54.13 per share. This transaction amounted to 32% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Hardik has been a net seller over the last 12 months, reducing personal holdings by ₹59m. Reported Earnings • Oct 14
Second quarter 2025 earnings released: EPS: ₹1.00 (vs ₹0.75 in 2Q 2024) Second quarter 2025 results: EPS: ₹1.00 (up from ₹0.75 in 2Q 2024). Revenue: ₹292.1m (up 26% from 2Q 2024). Net income: ₹10.0m (up 33% from 2Q 2024). Profit margin: 3.4% (up from 3.2% in 2Q 2024). Over the last 3 years on average, earnings per share has increased by 17% per year but the company’s share price has fallen by 1% per year, which means it is significantly lagging earnings. Tillkännagivande • Oct 08
Trident Texofab Limited to Report Q2, 2025 Results on Oct 12, 2024 Trident Texofab Limited announced that they will report Q2, 2025 results at 3:30 PM, Indian Standard Time on Oct 12, 2024 Tillkännagivande • Aug 22
Trident Texofab Limited, Annual General Meeting, Sep 27, 2024 Trident Texofab Limited, Annual General Meeting, Sep 27, 2024, at 16:00 Indian Standard Time. Valuation Update With 7 Day Price Move • Jul 25
Investor sentiment improves as stock rises 15% After last week's 15% share price gain to ₹44.56, the stock trades at a trailing P/E ratio of 23.6x. Average trailing P/E is 49x in the Retail Distributors industry in India. Total returns to shareholders of 23% over the past three years. Reported Earnings • Jul 20
First quarter 2025 earnings released: EPS: ₹0.69 (vs ₹0.13 loss in 1Q 2024) First quarter 2025 results: EPS: ₹0.69 (up from ₹0.13 loss in 1Q 2024). Revenue: ₹265.8m (up 15% from 1Q 2024). Net income: ₹6.96m (up ₹8.24m from 1Q 2024). Profit margin: 2.6% (up from net loss in 1Q 2024). Over the last 3 years on average, earnings per share has increased by 17% per year but the company’s share price has only increased by 5% per year, which means it is significantly lagging earnings growth. Tillkännagivande • Jul 13
Trident Texofab Limited to Report Q1, 2025 Results on Jul 17, 2024 Trident Texofab Limited announced that they will report Q1, 2025 results on Jul 17, 2024 Recent Insider Transactions • Jul 02
MD & Executive Chairman recently sold ₹4.5m worth of stock On the 27th of June, Hardik Desai sold around 94k shares on-market at roughly ₹48.33 per share. This transaction amounted to 2.2% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. This was Hardik's only on-market trade for the last 12 months. Valuation Update With 7 Day Price Move • Jul 01
Investor sentiment deteriorates as stock falls 16% After last week's 16% share price decline to ₹40.16, the stock trades at a trailing P/E ratio of 37.5x. Average trailing P/E is 50x in the Retail Distributors industry in India. Total returns to shareholders of 4.9% over the past three years. Reported Earnings • Feb 15
Third quarter 2024 earnings released: EPS: ₹0.55 (vs ₹1.14 in 3Q 2023) Third quarter 2024 results: EPS: ₹0.55 (down from ₹1.14 in 3Q 2023). Revenue: ₹231.2m (down 5.8% from 3Q 2023). Net income: ₹5.58m (down 52% from 3Q 2023). Profit margin: 2.4% (down from 4.7% in 3Q 2023). Over the last 3 years on average, earnings per share has increased by 44% per year but the company’s share price has only increased by 29% per year, which means it is significantly lagging earnings growth. Tillkännagivande • Feb 07
Trident Texofab Limited to Report Q3, 2024 Results on Feb 14, 2024 Trident Texofab Limited announced that they will report Q3, 2024 results on Feb 14, 2024 Tillkännagivande • Oct 28
Trident Texofab Limited to Report Q2, 2024 Results on Nov 06, 2023 Trident Texofab Limited announced that they will report Q2, 2024 results on Nov 06, 2023 Tillkännagivande • Oct 12
Trident Texofab Limited Announces Resignation of Deepak Prakashchandra Gandhi from the Board Trident Texofab Limited informed that Mr. Deepak Prakashchandra Gandhi has vide his resignation letter dated October 11, 2023, resigned from the Board of the Company with effect from the closure of business hours on 11th October, 2023. Valuation Update With 7 Day Price Move • Sep 11
Investor sentiment improves as stock rises 21% After last week's 21% share price gain to ₹73.75, the stock trades at a trailing P/E ratio of 40.1x. Average trailing P/E is 39x in the Retail Distributors industry in India. Total returns to shareholders of 157% over the past three years. Reported Earnings • Aug 12
First quarter 2024 earnings released: ₹0.13 loss per share (vs ₹0.23 profit in 1Q 2023) First quarter 2024 results: ₹0.13 loss per share (down from ₹0.23 profit in 1Q 2023). Revenue: ₹231.8m (flat on 1Q 2023). Net loss: ₹1.29m (down 154% from profit in 1Q 2023). Over the last 3 years on average, earnings per share has increased by 70% per year but the company’s share price has only increased by 15% per year, which means it is significantly lagging earnings growth. Tillkännagivande • Jul 29
Trident Texofab Limited to Report Q1, 2024 Results on Aug 10, 2023 Trident Texofab Limited announced that they will report Q1, 2024 results on Aug 10, 2023 Tillkännagivande • Jul 16
Trident Texofab Limited Announces Resignation of Vrusti Bhumik Patel as Independent Director Trident Texofab Limited announced that Mrs. Vrusti Bhumik Patel has vide her resignation letter dated 15 July 2023, resigned from the board of the company with effect from the closure of business hours on 15 July 2023. Board Change • Jul 01
Insufficient new directors There is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 4 experienced directors. 2 highly experienced directors. Executive & Non-Independent Director Manish Halwawala was the last director to join the board, commencing their role in 2020. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Tillkännagivande • Jun 04
Trident Texofab Limited Announces Resignation of Rushi Hemantkumar Jagani as Director Trident Texofab Limited announced that Mr. Rushi Hemantkumar Jagani has vide his resignation letter dated June 2, 2023, resigned from the Board Of the Company with effect from the closure of business hours on 02nd June, 2023. Due to personal reasons and pre-occupation elsewhere and there is no other material reason for resignation. Valuation Update With 7 Day Price Move • Apr 05
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to ₹63.55, the stock trades at a trailing P/E ratio of 22.6x. Average trailing P/E is 27x in the Retail Distributors industry in India. Total returns to shareholders of 47% over the past three years. Valuation Update With 7 Day Price Move • Feb 07
Investor sentiment deteriorates as stock falls 18% After last week's 18% share price decline to ₹66.05, the stock trades at a trailing P/E ratio of 23.5x. Average trailing P/E is 33x in the Retail Distributors industry in India. Total returns to shareholders of 80% over the past three years. Reported Earnings • Jan 18
Third quarter 2023 earnings released: EPS: ₹1.14 (vs ₹0.15 in 3Q 2022) Third quarter 2023 results: EPS: ₹1.14 (up from ₹0.15 in 3Q 2022). Revenue: ₹252.9m (up 6.0% from 3Q 2022). Net income: ₹11.5m (up ₹10.0m from 3Q 2022). Profit margin: 4.5% (up from 0.6% in 3Q 2022). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 55% per year but the company’s share price has only increased by 36% per year, which means it is significantly lagging earnings growth. Tillkännagivande • Jan 10
Trident Texofab Limited to Report Q3, 2023 Results on Jan 16, 2023 Trident Texofab Limited announced that they will report Q3, 2023 results at 3:30 PM, Indian Standard Time on Jan 16, 2023 Tillkännagivande • Jan 03
Trident Texofab Limited Appoints Rahul Jariwala as Company Secretary and Compliance Officer Trident Texofab Limited has approved the appointment of Mr. Rahul Jariwala as a Company Secretary and Compliance officer of the company with effective from 02 January, 2023. Valuation Update With 7 Day Price Move • Dec 07
Investor sentiment improved over the past week After last week's 25% share price gain to ₹102, the stock trades at a trailing P/E ratio of 56.5x. Average trailing P/E is 43x in the Retail Distributors industry in India. Total returns to shareholders of 170% over the past three years. Tillkännagivande • Oct 12
Trident Texofab Limited Approves Resignation of Sanju Patel as Company Secretary and Compliance Officer Trident Texofab Limited at its meeting held on October 11, 2022, the Board of Directors approved resignation of Ms. Sanju Patel from the post of Company Secretary and Compliance Officer, effective closure of business hours on October 11, 2022 due to her personal reasons. Reported Earnings • Oct 12
Second quarter 2023 earnings released: EPS: ₹0.77 (vs ₹0.02 in 2Q 2022) Second quarter 2023 results: EPS: ₹0.77 (up from ₹0.02 in 2Q 2022). Net income: ₹7.77m (up ₹7.62m from 2Q 2022). Over the last 3 years on average, earnings per share has increased by 26% per year but the company’s share price has increased by 53% per year, which means it is tracking significantly ahead of earnings growth. Tillkännagivande • Oct 05
Trident Texofab Limited to Report Q2, 2023 Results on Oct 11, 2022 Trident Texofab Limited announced that they will report Q2, 2023 results on Oct 11, 2022 Tillkännagivande • Aug 23
Trident Texofab Limited, Annual General Meeting, Sep 26, 2022 Trident Texofab Limited, Annual General Meeting, Sep 26, 2022, at 11:00 Indian Standard Time. Location: 5th Floor, Office Building Nr. Sahara Darwaja Surat India Recent Insider Transactions • Aug 09
MD & Executive Chairman recently sold ₹3.6m worth of stock On the 4th of August, Hardik Desai sold around 32k shares on-market at roughly ₹114 per share. In the last 3 months, they made an even bigger sale worth ₹5.9m. Hardik has been a seller over the last 12 months, reducing personal holdings by ₹12m. Tillkännagivande • Jul 09
Trident Texofab Limited Announces Resignation of Board Members Trident Texofab Limited announced the resignation of Ms. Ami Ashwinbhai Desai and inducting Mrs. Natasha Karbhari, Independent Director as new Member of the Audit Committee, Nomination & Remuneration Committee and member of Relationship Committee, with immediate effect. Tillkännagivande • Jul 07
Trident Texofab Limited to Report Q1, 2023 Results on Jul 12, 2022 Trident Texofab Limited announced that they will report Q1, 2023 results at 3:30 PM, Indian Standard Time on Jul 12, 2022 Tillkännagivande • Jul 02
Trident Texofab Limited Announces Resignation of Ami Ashwinbhai Desai as Independent Director Trident Texofab Limited informed that Ms. Ami Ashwinbhai Desai has tendered her resignation due to her personal reasons and other professional commitments as an Independent Director from the Board of Directors of the Company vide her letter dated July 1, 2022 effective the closure of business hours on 09th July, 2022. Recent Insider Transactions • Jun 07
MD & Executive Chairman recently sold ₹707k worth of stock On the 3rd of June, Hardik Desai sold around 7k shares on-market at roughly ₹101 per share. In the last 3 months, they made an even bigger sale worth ₹5.9m. Hardik has been a seller over the last 12 months, reducing personal holdings by ₹8.2m. Recent Insider Transactions • May 28
MD & Executive Chairman recently sold ₹5.9m worth of stock On the 25th of May, Hardik Desai sold around 60k shares on-market at roughly ₹98.89 per share. This was the largest sale by an insider in the last 3 months. Hardik has been a seller over the last 12 months, reducing personal holdings by ₹7.5m. Recent Insider Transactions • Apr 30
MD & Executive Chairman recently sold ₹5.6m worth of stock On the 27th of April, Hardik Desai sold around 55k shares on-market at roughly ₹103 per share. This was the largest sale by an insider in the last 3 months. This was Hardik's only on-market trade for the last 12 months. Reported Earnings • Apr 27
Full year 2022 earnings released: EPS: ₹0.98 (vs ₹0.35 in FY 2021) Full year 2022 results: EPS: ₹0.98 (up from ₹0.35 in FY 2021). Revenue: ₹850.3m (up 70% from FY 2021). Net income: ₹9.83m (up 178% from FY 2021). Profit margin: 1.2% (up from 0.7% in FY 2021). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 16% per year but the company’s share price has increased by 34% per year, which means it is well ahead of earnings. Tillkännagivande • Apr 16
Trident Texofab Limited to Report Q4, 2022 Results on Apr 21, 2022 Trident Texofab Limited announced that they will report Q4, 2022 results on Apr 21, 2022 Valuation Update With 7 Day Price Move • Feb 07
Investor sentiment improved over the past week After last week's 18% share price gain to ₹63.35, the stock trades at a trailing P/E ratio of 72.5x. Average trailing P/E is 49x in the Retail Distributors industry in India. Total returns to shareholders of 58% over the past three years. Reported Earnings • Oct 22
Second quarter 2022 earnings released: EPS ₹0.02 (vs ₹0.14 in 2Q 2021) The company reported a mediocre second quarter result with weaker earnings and profit margins, although revenues improved. Second quarter 2022 results: Revenue: ₹212.9m (up 36% from 2Q 2021). Net income: ₹157.0k (down 89% from 2Q 2021). Profit margin: 0.1% (down from 0.9% in 2Q 2021). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 30% per year but the company’s share price has increased by 4% per year, which means it is well ahead of earnings. Valuation Update With 7 Day Price Move • Oct 18
Investor sentiment improved over the past week After last week's 28% share price gain to ₹50.55, the stock trades at a trailing P/E ratio of 48.6x. Average trailing P/E is 53x in the Retail Distributors industry in India. Total returns to shareholders of 23% over the past three years. Valuation Update With 7 Day Price Move • Sep 14
Investor sentiment improved over the past week After last week's 21% share price gain to ₹40.00, the stock trades at a trailing P/E ratio of 38.7x. Average trailing P/E is 52x in the Retail Distributors industry in India. Total loss to shareholders of 5.3% over the past three years. Reported Earnings • Jul 02
Full year 2021 earnings released: EPS ₹0.35 (vs ₹0.90 in FY 2020) The company reported a poor full year result with weaker earnings, revenues and profit margins. Full year 2021 results: Revenue: ₹499.3m (down 45% from FY 2020). Net income: ₹3.53m (down 59% from FY 2020). Profit margin: 0.7% (down from 0.9% in FY 2020). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has fallen by 37% per year but the company’s share price has only fallen by 6% per year, which means it has not declined as severely as earnings. Executive Departure • Apr 21
Non-Executive Non-Independent Director has left the company On the 15th of April, Maniya Desai's tenure as Non-Executive Non-Independent Director ended after 3.9 years in the role. As of December 2020, Maniya personally held only 98.20k shares (₹3.0m worth at the time). A total of 2 executives have left over the last 12 months. Executive Departure • Apr 02
Company Secretary & Compliance Officer has left the company On the 31st of March, Mehul Amareliya's tenure as Company Secretary & Compliance Officer ended after 3.1 years in the role. We don't have any record of a personal shareholding under Mehul's name. Mehul is the only executive to leave the company over the last 12 months. Reported Earnings • Feb 12
Third quarter 2021 earnings released: EPS ₹0.08 (vs ₹0.24 in 3Q 2020) The company reported a poor third quarter result with weaker earnings, revenues and profit margins. Third quarter 2021 results: Revenue: ₹140.0m (down 30% from 3Q 2020). Net income: ₹790.0k (down 66% from 3Q 2020). Profit margin: 0.6% (down from 1.2% in 3Q 2020). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has fallen by 36% per year but the company’s share price has only fallen by 15% per year, which means it has not declined as severely as earnings. Tillkännagivande • Feb 05
Trident Texofab Limited to Report Q3, 2021 Results on Feb 11, 2021 Trident Texofab Limited announced that they will report Q3, 2021 results on Feb 11, 2021 Is New 90 Day High Low • Feb 02
New 90-day low: ₹24.25 The company is down 7.0% from its price of ₹26.00 on 04 November 2020. The Indian market is up 22% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Retail Distributors industry, which is up 30% over the same period. Is New 90 Day High Low • Dec 12
New 90-day high: ₹33.10 The company is up 20% from its price of ₹27.50 on 11 September 2020. The Indian market is up 17% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Retail Distributors industry, which is up 14% over the same period. Is New 90 Day High Low • Nov 25
New 90-day high: ₹30.00 The company is up 2.0% from its price of ₹29.30 on 27 August 2020. The Indian market is up 10.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Retail Distributors industry, which is up 7.0% over the same period. Reported Earnings • Nov 13
Second quarter 2021 earnings released: EPS ₹0.14 The company reported a decent second quarter result with improved earnings and profit margins, although revenues were weaker. Second quarter 2021 results: Revenue: ₹158.2m (down 29% from 2Q 2020). Net income: ₹1.45m (up 5.5% from 2Q 2020). Profit margin: 0.9% (up from 0.6% in 2Q 2020). The increase in margin was driven by lower expenses. Tillkännagivande • Nov 06
Trident Texofab Limited to Report Q2, 2021 Results on Nov 11, 2020 Trident Texofab Limited announced that they will report Q2, 2021 results on Nov 11, 2020 Is New 90 Day High Low • Oct 26
New 90-day low: ₹26.15 The company is down 14% from its price of ₹30.31 on 27 July 2020. The Indian market is up 9.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Retail Distributors industry, which is up 8.0% over the same period. Is New 90 Day High Low • Oct 08
New 90-day low: ₹26.40 The company is down 11% from its price of ₹29.58 on 10 July 2020. The Indian market is up 9.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Retail Distributors industry, which is up 13% over the same period. Tillkännagivande • Aug 18
Trident Texofab Limited to Report Q1, 2021 Results on Aug 20, 2020 Trident Texofab Limited announced that they will report Q1, 2021 results on Aug 20, 2020 Tillkännagivande • Jun 20
Trident Texofab Limited to Report Q4, 2020 Results on Jun 25, 2020 Trident Texofab Limited announced that they will report Q4, 2020 results on Jun 25, 2020 
